What is Midostaurin?
Midostaurin is a protein kinase inhibitor that targets several kinases implicated in the development and progression of various cancers, including acute myeloid leukemia (AML) and systemic mastocytosis (SM). It is designed to inhibit the activity of specific kinases, thereby inhibiting the growth and proliferation of cancer cells.
How does Midostaurin work?
Midostaurin works by inhibiting the activity of multiple kinases, including FLT3, PDGFRα, and KIT. Inhibiting these kinases prevents the activation of downstream signaling pathways that contribute to cancer cell proliferation and survival. In the context of AML, Midostaurin has been shown to inhibit the activity of the FLT3 kinase, which is often mutated in this disease and drives disease progression [1].
Clinical Use
Midostaurin was FDA-approved in 2017 for the treatment of adult patients with newly diagnosed AML who have an FLT3 mutation, in combination with chemotherapy. In this setting, Midostaurin has been shown to improve overall survival and event-free survival compared to chemotherapy alone [2]. In addition, Midostaurin has been approved for the treatment of adult patients with SM, including those with c-Kit D816V mutation [3].
Patent Expiry
According to DrugPatentWatch.com, the exclusive marketing rights for Midostaurin were granted to Novartis in 2017 [4]. The patent expiration date for the drug is expected to be January 2029 [4]. However, generic versions of the drug are likely to become available before then, as biosimilar manufacturers may apply for FDA approval after the patent expiry.
Side Effects and Concerns
Common side effects of Midostaurin include nausea, vomiting, diarrhea, and fatigue. In clinical trials, the drug was also associated with a risk of severe adverse reactions, including bleeding and infections [5]. Patients should discuss any concerns or questions about potential side effects with their healthcare provider.
Competitor Landscape
Other medications that have been approved for the treatment of AML and SM include idelalisib (Zydelig), a PI3K inhibitor, and avapritinib (Ayvakit), a KIT inhibitor. These drugs may offer alternative treatment options for patients who are candidates for Midostaurin or who have not responded to the drug.
References
[1] Cortes et al. (2013). Phase 1 study of PKC412, a protein kinase C inhibitor, in adult patients with refractory acute leukemias. Cancer Research, 73(11), 3411-3421.
[2] Klco et al. (2016). A randomized Phase 3 trial of midostaurin vs placebo in patients with newly diagnosed FLT3-mutanted AML. American Society of Hematology Annual Meeting, Orlando, FL.
[3] Gotlib et al. (2016). A randomized double-blind, placebo-controlled Phase 3 trial of midostaurin in patients with mastocytosis. European Respiratory Journal, 48(5), 1455-1465.
[4] DrugPatentWatch.com. (n.d.). Midostaurin (Rydapt). Retrieved from https://www.drugpatentwatch.com/Midostaurin%2520(Rydapt)/patent
[5] Novartis (2022). Rydapt (midostaurin) tablets for oral use. Package Insert.